Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: J Cell Physiol. 2017 Sep 28;233(3):2398–2408. doi: 10.1002/jcp.26111

Figure 5.

Figure 5

GSK-3β inhibition decreases the number of osteoclasts in tibial bone underneath the implant but not in the intact femoral bone. Measurements of osteoclast number per bone surface in the tibial implant bone (A) and the intact femoral bone (B). Analysis of the serum levels of TRAP5b by ELISA at 0, 3 and 5 days (C). Representative TRAP immunohistochemistry of tibial bone under the implant at days 3 and 5 (D). Boxplots indicate median as well as maximum and minimum in each group. a: significant compared to vehicle-treated animals, b: significant changes compared to controls. A p-value of <0.05 was considered significant.